• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Intravenous thrombolytic treatment of acute ischemic stroke in patients older and younger than 80 years: experience from one hospital (p4.275)
Conclusions:We found that IV thrombolysis still has benefit in people older than 80 years old but treatment decision should be taken with caution in well selected cases.Study Supported by: Not applicableDisclosure: Dr. Bayona has nothing to disclose. Dr. Diaz-Cruz has received research support from EMD Serono and Verily. Dr. Valencia-Mendoza has nothing to disclose. Dr. Díaz has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bayona, H., Diaz-Cruz, C., Valencia-Mendoza, C., Diaz, A. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Myocardial Wall Rupture Following tPA Administration: A Case Report and Review of the Literature (P3.270)
Conclusions:Although the frequency of pericarditis, mural hemorrhage and subsequent myocardial rupture after MI is declining following PCI, clinicians should be mindful of this potential complication in tPA treated patients with recent MI. Further, cardiac wall rupture should be considered in patients who develop acute hypotension and bradycardia following tPA administration. The current literature is limited and insufficient to provide generalizable guidance on managing AIS patients with recent MI.Disclosure: Dr. Neu has nothing to disclose. Dr. Albright has nothing to disclose. Dr. Lyerly has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Neu, M., Albright, K., Lyerly, M. Tags: Cerebrovascular Disease Case Reports II Source Type: research

Local Experience with a new retrievable stent (ERIC) in academic Center (P5.269)
Conclusions:In this study, the use of new ERIC retrieval device was technically feasible, safe, and effective in acute ischemic stroke with large-vessel occlusionDisclosure: Dr. Alshaer has nothing to disclose. Dr. Alturkustani has nothing to disclose. Dr. Khoja has nothing to disclose. Dr. Almekhlafi has nothing to disclose. Dr. Ayoub has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: AlShaer, D., Alturkustani, A., Khoja, A., Almekhlafi, M., Ayoub, O. Tags: Acute Cerebrovascular Interventional Therapies Source Type: research

Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke
Conclusions: IV alteplase promotes measurable reduction in HAS regardless of HAS location or extent. Alteplase increased independence at 6 months in patients with and without HAS. Classification of evidence: This study provides Class I evidence that for patients within 6 hours of ischemic stroke with a CT hyperdense artery sign, IV alteplase reduced intra-arterial hyperdense thrombus.
Source: Neurology - January 11, 2016 Category: Neurology Authors: Mair, G., von Kummer, R., Morris, Z., von Heijne, A., Bradey, N., Cala, L., Peeters, A., Farrall, A. J., Adami, A., Potter, G., Cohen, G., Sandercock, P. A. G., Lindley, R. I., Wardlaw, J. M., For the IST-3 Collaborative Group Tags: CT, Clinical trials Randomized controlled (CONSORT agreement), Class I, Infarction ARTICLE Source Type: research

Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument
Conclusion: A simpler model using a 3-item stroke severity score, instead of the 15-item NIH Stroke Scale, has similar prognostic value and may be easier to use in routine care. Future studies are needed to test whether it can improve process and clinical outcomes.
Source: Neurology - September 14, 2015 Category: Neurology Authors: Kent, D. M., Ruthazer, R., Decker, C., Jones, P. G., Saver, J. L., Bluhmki, E., Spertus, J. A. Tags: All Cerebrovascular disease/Stroke ARTICLE Source Type: research

To determine the impact of serum albumin levels on admission with the outcomes in patients receiving IV-t-PA (alteplase) for treatment of acute ischemic stroke. (P5.134)
Conclusion: Among ischemic stroke patients treated with thrombolysis admission hypoalbuminemia was not a predictor of poor outcome. This will need to be validated in larger studies.Disclosure: Dr. Limaye has nothing to disclose. Dr. Lahoti has nothing to disclose. Dr. Hinduja has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Limaye, K., Lahoti, S., Hinduja, A. Tags: Cerebrovascular Disease and Interventional Neurology: Biomarkers and Emerging Science Source Type: research

Embolic stroke with spontaneous recanalization (P3.085)
Conclusions This study infers that thrombolysis remarkably improves clinical outcome in patients with embolic stroke who do not have visible arterial occlusion at presentation. A prospective study to validate these results is being planned.Disclosure: Dr. Lahoti has nothing to disclose. Dr. Gokhale has nothing to disclose. Dr. Caplan has received personal compensation in an editorial capacity for JAMA Neurology. Dr. Michel has received personal compensation for activities with Servier, Sanofi-Aventis Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals, as a speaker, steering committee member, and/or advisory board me...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Lahoti, S., Gokhale, S., Caplan, L., Michel, P., Samson, Y., Rosso, C., Limaye, K., Hinduja, A., Singhal, A., Ali, S., Kryscio, R., Dedhia, N., Hastak, S., Liebeskind, D., Pettigrew, L. Tags: Cerebrovascular Disease and Interventional Neurology: Hemorrhagic and Ischemic Stroke Source Type: research

Urticarial allergic reaction to alteplase: A case report (P6.243)
CONCLUSIONS: Physicians treating acute ischemic stroke with alteplase should be aware of this uncommon but potentially dangerous complication in the spectrum of anaphylactic reactions.Disclosure: Dr. Papolin has nothing to disclose. Dr. Mendes has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Harger has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Chamma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Papolin, L., Mendes, D., Lange, M., Germiniani, F., Harger, R., Zetola, V., Chamma, J. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research

"Heparin-Less" Protocol for Endovascular Treatment of Acute Ischemic Stroke (P4.209)
Conclusions: We observed "heparin less" endovascular treatment results in high rates of recanalization with an acceptable rate of post thrombolytic ICH.Disclosure: Dr. Khan has nothing to disclose. Dr. Hassan has nothing to disclose. Dr. Zafar has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Khan, A., Hassan, A., Zafar, T., Malik, A., Adil, M., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research

Stroke Outcomes and Usage of IV Alteplase during Pregnancy in the Nationwide Inpatient Sample 2005-2010 (P3.100)
ConclusionsStroke remains a serious complication in pregnancy, and mortality is increasing. Usage of tPA for AIS during pregnancy is minimal, with increased mortality compared to all strokes in pregnancy. Research efforts are needed to improve stroke outcomes during pregnancy.Disclosure: Dr. Ouyang has nothing to disclose. Dr. Knopf has nothing to disclose. Dr. Conners has nothing to disclose. Dr. Cutting has received personal compensation for activities with F1000. Dr. Lee has nothing to disclose. Dr. Smit has nothing to disclose. Dr. Kuklina has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Song, S., Ouyang, B., Knopf, T., Conners, J., Cutting, S., Lee, V., Smit, L., Kuklina, E. Tags: Cerebrovascular Disease and Interventional Neurology: t-PA Source Type: research

The Elusive Golden Hour - A Multicenter Analysis of the Difficulties of Timely Intravenous Alteplase Treatment (P03.189)
CONCLUSIONS: Many factors contribute to delay in IV thrombolytic treatment in the acute stroke patient. In many patients when stabilization is needed or when the clinical presentation is confusing, it may be in the patient's best interest to delay thrombolytics until the situation is clarified. We must strive to identify causes of delay in our institutions to maintain maximum benefit of thrombolytic therapy for our patients.Disclosure: Dr. Sugg has received personal compensation for activities with Genetech as a speaker. Dr. Chaudhrey has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Ehtisham has nothing to di...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sugg, R., Chaudhrey, B., Chen, S., Ehtisham, A., Summers, D., Rymer, M. Tags: P03 Cerebrovascular Disease III Source Type: research

"Fou Rire Prodromique" as the Presentation of a Left Frontal Ischemic Stroke (P02.040)
CONCLUSIONS: Frontal lobe involvement affecting the Broca's area, as we described in our case, has only been described once. We conclude that the patient's laughter attack was the initial manifestation of the stroke suggesting that an acute infarct of Broca's area is capable of producing this unusual clinical presentation.Disclosure: Dr. Rosales has nothing to disclose. Dr. Garcia-Gracia has nothing to disclose. Dr. Salgado has received personal compensation in an editorial capacity from Belvoir Media Group as Consulting Editor of A Special Report published by the editors of Heart Advisor Cleveland Clinic STROKE: Advances ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Rosales, D., Garcia-Gracia, C., Salgado, E. Tags: P02 Cerebrovascular Disease II Source Type: research